Acyclovir Suppliers & Bulk Manufacturers
Available Forms: Lyophilized powder for injection
Available Strengths: 500 mg / vial
Reference Brands: Zovirax®(US & EU)
Category:
Anti Viral
Acyclovir Injection (250 mg–1 g) is a vital antiviral for treating severe herpes infections, including HSV encephalitis and shingles. Available under brands like Zovirax®, it’s offered by WHO-GMP suppliers on PharmaB2B platforms for hospital procurement, tenders, and emergency care needs.
Acyclovir is available in Lyophilized powder for injection
and strengths such as 500 mg / vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Acyclovir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Acyclovir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Acyclovir Injection is a potent antiviral treatment used for managing severe HSV and VZV infections, including herpes encephalitis and neonatal herpes. Marketed under brands like Zovirax®, it is available as 250 mg, 500 mg, and 1 g lyophilized vials for IV administration. Acyclovir Injection is ideal for hospital settings and emergency care, particularly in immunocompromised patients. On PharmaB2B platforms, global buyers can bulk source WHO-GMP and USFDA-approved Acyclovir from reputable manufacturers. It remains a critical injectable antiviral in infectious disease protocols, ensuring timely and effective viral suppression where oral formulations are inadequate.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing